Form 8-K

8-K — INTELLIGENT BIO SOLUTIONS INC.

Accession: 0001493152-26-039140

Filed: 2026-08-19

Period: 2026-08-19

CIK: 0001725430

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001725430

2026-08-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date

of Report (Date of Earliest Event Reported): August 19, 2026

INTELLIGENT

BIO SOLUTIONS INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State

Incorporation)

(Commission

File

Number)

(IRS

employer

identification

no.)

135

West 41st Street, 5th Floor

New

York, NY 10036

(Address

of principal executive offices, including zip code)

Registrant’s

telephone number, including area code: (646) 790-5756

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.01 par value

INBS

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

August 19, 2026, Intelligent Bio Solutions Inc. (the “Company”) issued a press release (the “Press Release”)

announcing financial results for the three months and full fiscal year ended June 30, 2026. A copy of the Press Release is furnished

as Exhibit 99.1 to this Current Report on Form 8-K.

The

information furnished in this Current Report on Form 8-K under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities

Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference

in such filing.

Item

9.01 Financial Statements and Exhibits.

No.

Description

99.1

Press release dated August 19, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date: August 19, 2026

INTELLIGENT BIO SOLUTIONS INC.

By:

/s/ Spiro Sakiris

Name:

Spiro Sakiris

Title:

Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Intelligent

Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge

Growth

Reader

installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Full

year gross profit margin expanded to 48.63%, up 778 basis points year-over-year

502

active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries

Company

made substantial progress toward FDA clearance and planned market expansion during the year

NEW

YORK, August 19, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a

medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational

highlights for the full year ended June 30, 2026, and provided a business update.

“Fiscal

2026 was a year of clear, compounding progress across every aspect of our business,” said Harry Simeonidis, President and CEO

at Intelligent Bio Solutions. “We delivered record annual revenue of $4.2 million, a 38% increase year-over-year, driven by

a 22% expansion in our reader installed base and a 35% increase in consumable cartridges. Our razor-razorblade model is gaining scale,

with hardware placements generating the installed base and growing consumable utilization delivering recurring revenue. Entering fiscal

2027, we are focused on three priorities: sustaining the operational improvements driving gross margin expansion, continuing to accelerate

commercial growth, and advancing our FDA regulatory program toward planned U.S. market entry. To that end, we have completed all clinical

data collection across our FDA 510(k) clinical study program. Analysis of collected data is underway, and we remain on track for our

FDA submission.”

“The

financial results for fiscal 2026 reflect a business that is scaling with improving unit economics,” said Spiro Sakiris, CFO

at Intelligent Bio Solutions. “Full-year gross profit grew 64% to $2.05 million and gross margin expanded 778 basis points to

48.63%. These improvements are a result of our transition to Syrma Johari as a high-quality, lower-cost manufacturing partner, an optimized

product mix weighted toward higher-margin cartridge consumables, and the operational leverage that comes from growing volumes across

a more efficient production base. Our sustained investment in marketing, sales, product awareness, and customer support has been the

direct commercial driver behind our 38% revenue growth and the expanding utilization we are seeing across our installed base.”

Full

Year Fiscal 2026 Financial Highlights

● Total

revenue of $4,215,175, up 38% year-over-year from $3,052,532.

● Revenue

increase of $1,162,643 year-over-year.

● Gross

profit of $2,049,994, up 64% year-over-year from $1,246,859.

● Gross

profit margin of 48.63%, up from 40.85% - an improvement of 778 basis points.

● Reader

installed base of 1,886 units as of June 30, 2026, up 22% from 1,545 units as of June 30,

2025.

● Total

consumable cartridges of 106,500 units, up 35% from 78,750 in fiscal 2025.

● 502

active customers as of June 30, 2026.

Progress

Toward FDA Clearance and U.S. Market Expansion

INBS

made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar

U.S. drug screening market beyond current Forensic Use Only settings. The Company’s regulatory program accelerated significantly,

underpinned by a series of clinical and technical studies:

● Initiated

and completed a clinical cut-off study evaluating codeine detection cut-off levels in 40

adults, advancing the clinical evidence base for the 510(k) program.

● Completed

penetration testing, with no major vulnerabilities identified, strengthening the cybersecurity

component of the submission package.

● Initiated

a multi-site method comparison study, designed to evaluate system accuracy when operated

by intended end-users. The study was completed in early fiscal 2027.

● Initiated

an interference study examining the impact of everyday substances on the Intelligent Fingerprinting

Drug Screening System. The study was completed in early fiscal 2027.

● Initiated

precision testing, evaluating reproducibility across varied manufacturing conditions and

operating environments. The study was completed in early fiscal 2027, confirming reproducibility

across more than 1,600 tests, three production runs, and three independent testing sites.

● Initiated

a usability study designed to evaluate how effectively operators could be trained to use

the Intelligent Fingerprinting Drug Screening System. The study was completed in early fiscal

2027.

● Initiated

validation study for a rapid drug screening cartridge targeting 70% faster results.

● Strengthened

the Company’s European intellectual property portfolio with its eighth patent grant,

further protecting its proprietary fingerprint drug screening technology.

● The

Company’s FDA 510(k) submission is on track for the second half of calendar 2026, progressing

toward planned entry into the U.S. market, the world’s largest drug screening market.

Commercial

Growth and Market Expansion

INBS

continued to expand its commercial presence across international markets throughout fiscal 2026, supported by targeted investment in

marketing, sales, and customer support infrastructure.

● Active

customer base grew to 502 accounts as of June 30, 2026.

● Reader

installed base expanded 22% to 1,886 units, with each new placement creating the recurring

consumable demand that underpins the Company’s revenue model.

● Total

consumable cartridges grew 35% to 106,500 units, outpacing the rate of installed base growth

and confirming deepening utilization among existing customers.

● Commercial

traction extended across safety-critical sectors including construction, manufacturing, transport

and logistics, and mining, with continued growth across the UK, Europe, APAC, and the Middle

East.

● Strategic

partnership secured with Bouygues UK, part of global construction group Bouygues Construction,

for a drug-testing rollout, adding a significant new customer in a high-profile, safety-critical

environment.

● Strategic

manufacturing transition to Syrma Johari, a high-quality, lower-cost manufacturing partner,

with initial production runs successfully completed and shipments underway. This partnership

is delivering a significant reduction in manufacturing costs, directly contributing to gross

margin expansion.

Operational

Efficiencies Strengthening Business Fundamentals

The

improvement in gross profit margin from 40.85% to 48.63% year-over-year reflects the structural progress INBS has made in its production

and commercial operations throughout fiscal 2026:

● The

transition of reader manufacturing is expected to be transformational for the Company’s

cost structure and is expected to support long-term margin improvement. This positions INBS

to achieve materially stronger unit economics as the installed base and production volumes

continue to grow.

● Increasing

economies of scale in manufacturing and distribution as production volumes grew.

● Continued

optimization of product mix, with higher-margin cartridge consumables representing a growing

proportion of total revenue.

● Increased

investment in customer support, contributing directly to higher consumables utilization rates

across the installed base and reinforcing recurring revenue generation.

About

Intelligent Bio Solutions Inc.

Intelligent

Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The

Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat

analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the

test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.

With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical

industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport

and logistics firms, mining, drug treatment organizations, and coroners.

For

more information, visit: https://ibs.inc/

Forward-Looking

Statements

Some

of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section

21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.

Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s

ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and

collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent

Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual

results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify

forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,”

“plans,” “projects,” “intends,” “potential,” “may,” “could,”

“might,” “will,” “should,” and “approximately,” or other words that convey uncertainty

of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and

unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the

U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release.

Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events

or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company

Contact

Intelligent

Bio Solutions Inc.

info@ibs.inc

Investor

& Media Contact

Valter

Pinto, Managing Director

KCSA

Strategic Communications

PH:

(212) 896-1254

INBS@kcsa.com

—

Financial tables to follow —

Intelligent

Bio Solutions Inc.

Consolidated

Balance Sheets

of June 30,

2026

2025

ASSETS

Current assets

Cash

and cash equivalents

$ 3,992,312

$ 1,019,909

Accounts

receivable, net

848,464

594,614

Inventories,

net

418,577

635,215

Research

and development tax incentive receivable

806,951

734,408

Assets

held for sale

327,500

Prepaid

expenses and other current assets

1,030,932

826,976

Total

current assets

7,097,236

4,138,622

Property and equipment, net

294,399

251,325

Operating lease right-of-use

assets

1,751,040

69,520

Intangibles,

net

2,799,161

3,790,319

Total

assets

$ 11,941,836

$ 8,249,786

LIABILITIES

AND SHAREHOLDERS’ EQUITY

Current liabilities

Accounts

payable and accrued expenses

$ 4,130,213

$ 4,534,246

Current

portion of operating lease liabilities

147,005

84,659

Current

employee benefit liabilities

651,706

534,990

Notes

payable

197,146

Total

current liabilities

4,928,924

5,351,041

Employee benefit liabilities,

less current portion

49,931

84,921

Operating

lease liabilities, less current portion

1,672,155

Total

liabilities

6,651,010

5,435,962

Commitments and contingencies

Shareholders’

equity

Common

stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026,

respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively*

29,056

7,324

Treasury

stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively*

(1 )

Additional

paid-in capital*

80,992,006

65,849,822

Accumulated

deficit

(74,964,040 )

(62,533,065 )

Accumulated

other comprehensive loss

(546,186 )

(327,944 )

Total

consolidated Intelligent Bio Solutions Inc. equity

5,510,835

2,996,136

Non-controlling

interest

(220,009 )

(182,312 )

Total

shareholders’ equity

5,290,826

2,813,824

TOTAL

LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 11,941,836

$ 8,249,786

Common

stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025,

throughout the consolidated financial statements unless otherwise stated.

Intelligent

Bio Solutions Inc.

Consolidated

Statements of Operations and Other Comprehensive Income (Loss)

Year

ended June 30,

2026

2025

Revenue

$ 4,215,175

$ 3,052,532

Cost

of revenue (exclusive of amortization shown separately below)

(2,165,181 )

(1,805,673 )

Gross profit

2,049,994

1,246,859

Other income

Government

support income

677,776

816,901

Operating expenses

Selling,

general and administrative expenses

(10,502,161 )

(8,918,468 )

Development

and regulatory approval expenses

(3,371,292 )

(2,396,513 )

Depreciation

and amortization

(1,163,847 )

(1,207,875 )

Impairment

of long-lived assets

(298,555 )

(220,062 )

Total

operating expenses

(15,335,855 )

(12,742,918 )

Loss from operations

(12,608,085 )

(10,679,158 )

Other income (expense), net

Interest

expense

(10,736 )

(26,339 )

Realized

foreign exchange gain (loss)

39,820

(911 )

Interest

income

110,329

101,522

Total

other income, net

139,413

74,272

Net loss

(12,468,672 )

(10,604,886 )

Net

loss attributable to non-controlling interest

(37,697 )

(36,153 )

Net

loss attributable to Intelligent Bio Solutions Inc.

$ (12,430,975 )

$ (10,568,733 )

Other comprehensive (loss)

income

Foreign

currency translation (loss) gain

(218,242 )

384,670

Total

other comprehensive (loss) income

(218,242 )

384,670

Comprehensive loss

(12,686,914 )

(10,220,216 )

Comprehensive

loss attributable to non-controlling interest

(37,697 )

(36,153 )

Comprehensive

loss attributable to Intelligent Bio Solutions Inc.

$ (12,649,217 )

$ (10,184,063 )

Net

loss per share, basic and diluted*

$ (8.44 )

$ (20.04 )

Weighted

average shares outstanding, basic and diluted*

1,472,744

527,364

Common

stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025,

throughout the consolidated financial statements unless otherwise stated.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 19, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 19, 2026

Entity File Number

001-39825

Entity Registrant Name

INTELLIGENT

BIO SOLUTIONS INC.

Entity Central Index Key

0001725430

Entity Tax Identification Number

82-1512711

Entity Incorporation, State or Country Code

Entity Address, Address Line One

135

West 41st Street

Entity Address, Address Line Two

5th Floor

Entity Address, City or Town

New

York

Entity Address, State or Province

Entity Address, Postal Zip Code

10036

City Area Code

(646)

Local Phone Number

790-5756

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.01 par value

Trading Symbol

INBS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration